Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

Objectives To determine the respective efficacy of quetiapine and rivastigmine for agitation in people with dementia in institutional care and to evaluate these treatments with respect to change in cognitive performance. Design Randomised double blind (clinician, patient, outcomes assessor) placebo...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Yayımlandı:	BMJ
Asıl Yazarlar:	Ballard, Clive, Margallo-Lana, Marisa, Juszczak, Edmund, Douglas, Simon, Swann, Alan, Thomas, Alan, O'Brien, John, Everratt, Anna, Sadler, Stuart, Maddison, Clare, Lee, Lesley, Bannister, Carol, Elvish, Ruth, Jacoby, Robin
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	BMJ Publishing Group 2005
Konular:	Papers
Online Erişim:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC556156/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15722369/ https://ncbi.nlm.nih.govhttps://doi.org/10.1136/bmj.38369.459988.8F
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

Benzer Materyaller